Thus, we studied the prognostic factors of AML patients with ASXL1 mutations and retrospectively compared the effects of HMAs and venetoclax on patient response and prognosis with those of IC and reduced‐intensity chemotherapy to explore the therapeutic and prognostic impacts of HMA and venetoclax. The gene discussed is ASXL1; the disease is acute myeloid leukemia.